SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-027951
Filing Date
2022-11-03
Accepted
2022-11-03 07:02:55
Documents
75
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q vnda-20220930.htm   iXBRL 10-Q 1241484
2 EX-31.1 vndaex311930202210q.htm EX-31.1 10584
3 EX-31.2 vndaex312930202210q.htm EX-31.2 10208
4 EX-32.1 vndaex321930202210q.htm EX-32.1 6776
  Complete submission text file 0001628280-22-027951.txt   5863160

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20220930.xsd EX-101.SCH 45497
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20220930_cal.xml EX-101.CAL 65576
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20220930_def.xml EX-101.DEF 196537
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20220930_lab.xml EX-101.LAB 520318
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20220930_pre.xml EX-101.PRE 354000
69 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20220930_htm.xml XML 918075
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 221356135
SIC: 2834 Pharmaceutical Preparations